---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196457"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:54:23.426260+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Galera settles Phase 3 ROMAN trial CRO lawsuit for $975,000

## Summary
- Settlement with Alira Health Clinical and IQVIA Biotech resolves breach-of-contract and negligence claims.
- CROs paid $975,000 in exchange for mutual releases and termination of contracts with no further obligations.
- Lawsuit stemmed from a 2021 error in statistical programming for the Phase 3 ROMAN trial of avasopasem.
- Galera expects to file a Praecipe to end the litigation by August 8, 2024.

## SEC filing metadata
- accession: 0001193125-24-196457
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312524196457/0001193125-24-196457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312524196457/d792052d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196457
- JSON: https://secwatch.observer/filing/0001193125-24-196457.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.